menu
    • menu

    Company profile for Denali Therapeutics

    NEW Drugs in Dev: 16
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Denali was founded by scientists, drug developers and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for patients suffering from neurodegenerative disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Denali TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    151 Oyster Point Blvd - South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.denalitherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Denali Unveils LSD Advances at 2026 WORLD Symposium
    Denali Unveils LSD Advances at 2026 WORLD Symposium

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233366/0/en/Denali-Therapeutics-Presents-Enzyme-TransportVehicle-Progress-Across-Three-Clinical-Programs-for-Treatment-of-Lysosomal-Storage-Disorders-at-2026-WORLDSymposium.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Denali Therapeutics Showcases Enzyme Transportvehicle Programs
    Denali Therapeutics Showcases Enzyme Transportvehicle Programs

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230197/0/en/Denali-Therapeutics-To-Host-Webcast-Highlighting-Presentations-on-Enzyme-TransportVehicle-Programs-at-the-2026-WORLDSymposium.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Sanofi Keeps Mum On Denali Pact After Scrapping Final RIPK1 Drug
    Sanofi Keeps Mum On Denali Pact After Scrapping Final RIPK1 Drug

    29 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sanofi-keeps-mum-future-denali-pact-after-scrapping-final-ripk1-inhibitor

    FIERCE BIOTECH
    29 Jan 2026
    Share Share
    Denali Therapeutics To Present Enzyme Transport Vehicle Data
    Denali Therapeutics To Present Enzyme Transport Vehicle Data

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3229066/0/en/Denali-Therapeutics-Announces-Data-Presentations-on-Enzyme-TransportVehicle-Programs-for-Hunter-Syndrome-Sanfilippo-Syndrome-Type-A-and-Pompe-Disease-at-Upcoming-2026-WORLDSymposiu.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Denali Pharma Reveals 2026 Focus: Tividenofusp Alfa Launch
    Denali Pharma Reveals 2026 Focus: Tividenofusp Alfa Launch

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213572/0/en/Denali-Therapeutics-Announces-Key-Anticipated-Milestones-and-Priorities-for-2026-Including-Commercial-Launch-of-Tividenofusp-Alfa-for-Hunter-Syndrome.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    NEJM Publishes Denali's DNL310 Phase 1/2 Hunter Study
    NEJM Publishes Denali's DNL310 Phase 1/2 Hunter Study

    30 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/30/3211341/0/en/The-New-England-Journal-of-Medicine-Publishes-Phase-1-2-Study-of-Denali-Therapeutics-Tividenofusp-Alfa-DNL310-for-Hunter-Syndrome-MPS-II.html

    GLOBENEWSWIRE
    30 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search